Combination therapies are certainly where it’s at for Merck and Keytruda at the moment, across all indications. This out of the US this morning:
https://www.fiercepharma.com/marketing/merck-s-keytruda-blockbuster-frontier-first-class-fda-approval-post-surgery-adjuvant?oly_enc_id=2993B0391467A3V
Ann: Phase II TACTI-002 trial recruitment successfully completed, page-5
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.8¢ | 29.0¢ | $320.7K | 1.090M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 43 | 290080 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 364467 | 17 |
View Market Depth
| Last trade - 13.59pm 11/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |